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Abstract
Background: A photochemical treatment (PCT) process
for inactivation of infectious pathogens and leukocytes
has been developed and evaluated using single-donor
platelet concentrates. This study assessed the applica-
tion of PCT to platelets prepared from pooled buffy coats.
In this study, in vitro functional characteristics of PCT
platelets were compared to control platelets prepared
from pooled buffy coats using the approved platelet-
additive solution T-Sol®. Platelets in platelet PAS III addi-
tive solution without PCT were evaluated as well. PCT
also included the use of a psoralen (S-59) reduction
device (SRD). Materials and Methods: Four types of
platelet concentrates were compared: (1) platelet con-
centrate in plasma/T-Sol; (2) platelet concentrate in plas-
ma/PAS III; (3) platelet concentrate in plasma/PAS III,
PCT, 9 h SRD and (4) platelet concentrate in plasma/
PAS III, PCT, 16 h SRD. PCT occurred on the day after
whole-blood collection. In vitro assay parameters in-
cluded: pH, pO2, pCO2, HCO–3, platelet count, mean plate-
let volume, plasma glucose, plasma lactate, total ATP,
expression of p-selectin, hypotonic shock response and
electron microscopy. Results: The results indicate that
PCT is compatible with platelet concentrates prepared
from pooled buffy coats for up to 7 days of storage. Con-
clusion: The PCT process resulted in acceptable in vitro
platelet functional characteristics and is currently in clini-
cal trials to evaluate the haemostatic efficacy of PCT
platelets in thrombocytopenic patients requiring multi-
ple platelet transfusions.
Copyright © 2000 S. Karger AG, Basel
Introduction
A photochemical treatment (PCT) process utilizing the
psoralen (S-59) and long wavelength ultraviolet light
(UVA, 320–400 nm) has been developed for treatment of
platelet concentrates [1, 2]. PCT with S-59 and UVA is a
nucleic-acid-specific inactivation process with a broad
spectrum of activity against bacteria, viruses and leuko-
cytes. S-59 reversibly intercalates into helical regions of
DNA and RNA. Upon illumination with UVA, S-59
reacts with pyrimidine bases to form covalent mono-
adducts and cross-links with nucleic acids. Bacteria, vi-
ruses or cells with genomes which have been modified by
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S-59 are unable to replicate. Platelets are non-nucleated
terminally differentiated cells which do not require nucle-
ic acid transcription and translation for haemostatic func-
tion. Retention of in vitro platelet properties during stor-
age does not require nucleic acid function [2]. This new
PCT process provides an ex vivo method to increase the
safety of platelet transfusion.
The efficacy of PCT has been demonstrated using sin-
gle-donor platelet concentrates. High levels of a broad
array of bacteria and viruses were inactivated in single-
donor platelet concentrates (3 ! 1011–5 ! 1011 platelets)
suspended in 300 ml of 35% plasma and 65% platelet
additive solution (PAS III) and exposed to 150 ÌM S-59
and a 3 J/cm2 treatment with UVA [2, 3]. Contaminating
leukocytes in platelet concentrates were inactivated by
PCT at an S-59 dose level that is 1,500-fold lower than
that used for bacterial and viral inactivation [4]. Follow-
ing PCT, in vitro platelet function was adequately pre-
served during 7 days of storage [2, 3].
The PCT process results in photodegradation of S-59.
After illumination and prior to transfusion, levels of resid-
ual S-59 and free photoproducts are reduced by treatment
of the illuminated platelet concentrates with an integral
S-59 reduction device (SRD). Platelets suspended in the
container with the integral SRD were incubated with
shaking in a temperature-controlled platelet incubator.
The purpose of the current study was to evaluate the in
vitro characteristics of platelets obtained from pooled
CPD buffy coats and submitted to the PCT process and
two different SRD conditions. The PCT platelets were
compared to control untreated platelets suspended in an
approved platelet additive solution T-Sol and also to
untreated platelets stored in PAS III. Three replicate
experiments were performed each using a pool of 20
ABO-compatible buffy coats. The four arms of the study
were: (1) first arm: platelet concentrate in plasma/T-Sol;
(2) second arm: platelet concentrate in plasma/PAS III;
(3) third arm: platelet concentrate in plasma/PAS III,
PCT, 9 h SRD, and (4) fourth arm: platelet concentrate in
plasma/PAS III, PCT, 16 h SRD.
Results from this study demonstrated that PCT is com-
patible with platelets prepared from pooled buffy coats. In
vitro platelet function, assessed by hypotonic shock re-
sponse, was not adversely affected during 7 days of stor-
age following PCT under conditions that inactivated bac-
teria, viruses and leukocytes.
Materials and Methods
Disposables – Wet Components
The platelet additive solutions and the S-59 solution were pro-
vided in PL 2411 containers with tubing (a non-PVC plastic material
made without a plasticizer; Baxter Healthcare Corporation, La
Châtre, France). They were added to buffy coat platelets using a ster-
ile connection device.
T-Sol® formulation
Sodium chloride 6.75 g
Sodium acetate, trihydrate 4.08 g
Sodium citrate, dihydrate 2.94 g
Water for injection 1,000 ml
pH 7.2
Volume 300 ml
PAS III formulation
Sodium chloride 4.52 g
Sodium acetate, trihydrate 4.42 g
Sodium citrate, dihydrate 3.18 g
Dibasic sodium phosphate, anhydrous 3.05 g
Monobasic sodium phosphate, dihydrate 1.05 g
Water for injection 1,000 ml
pH 7.2
Volume 280 ml
S-59 formulation
Sodium chloride 9.24 g
Psoralen S-59 1.01 g
Hydrochloric acid 1 N for pH adjustment
Water for injection 1,000 ml
pH 5.0–6.0
Volume 17.5 ml
Disposables – Dry Components
Whole blood was collected by using the Optipac® Triple bi-filled
kit (Baxter Healthcare). The kit consists of a primary ‘bottom and
top’ container filled with 70 ml of CPD anti-coagulant solution, a
secondary conventional container filled with 110 ml of SAG-M solu-
tion and an empty transfer container. Packs are made of PL 2209
plastic (a polyvinyl chloride (PVC) with a non-DEHP plasticizer). A
600-ml transfer pack with 8 leads was used to pool buffy coats (Baxt-
er Healthcare). The Optidock buffy coat leukodepletion set consists
of a Pall Autostop® buffy coat filter, specifically designed to remove
leukocytes in the production of platelets from buffy coats, and a 1.3-
litre PL 2410 plastic container. The platelet illumination container
was a 1-litre PL 2410 plastic container (Baxter Healthcare). The
platelet storage container was a 1.3-litre PL 2410 plastic container
(Baxter Healthcare).
S-59 Removal Device
The SRD consists of approximately 2.5 g of polystyrene beads
enclosed in a polyester mesh pouch with a 1-litre PL 2410 plastic
container.
Equipment
The Optipress II® (Baxter Healthcare Corporation, Nivelles, Bel-
gium) was used for separation of the blood collected and centrifuged
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in Optipac. The UVA illumination device (code No. 4R4440, Baxter
Healthcare Corp., Deerfield, Ill., USA) mounted on a reciprocal
platelet shaker (Helmer Labs, Noblesville, Ind., USA) was used for
illumination with a wavelenght of 320–400 nm. The UVA device is
air-cooled. The output of this device was approximately 15–20 mW/
cm2 permitting delivery of 3 J/cm2 in approximately 3–4 min.
Blood Processing
Preparation of Buffy Coats
Blood units of 500 ml B 10% were collected from volunteer
donors in 70 ml CPD anticoagulant solution using triple Optipac
(Baxter Healthcare). Selection of donors and the blood donation pro-
cedure were based on local standard practices. The whole blood units
were kept overnight (16–20 h) at room temperature (20 B 2°C).
High-speed centrifugation (4,650 g, 10 min) was applied to separate
cellular components from plasma (Beckman Instr. Inc., Fullerton,
Calif., USA). Buffy coats of 55 B 5 ml were separated from plasma
and packed red cells using the Optipress II standard procedure.
Preparation of Study Platelet Concentrates
Preparation of Pooled Buffy Coats. Using a sterile docking device
SCD312 (Terumo, Japan), a pool of 20 ABO-compatible buffy coats
was made in a 1.3-litre PL 2410 plastic container. After thorough
mixing, the pool was separated into equal volumes in four 600-ml
transfer packs. To one container the standard volume of approxi-
mately 300 ml T-Sol was added. To each of the three remaining con-
tainers 280 ml PAS III was added to reduce the plasma concentration
to 30–45% for optimal PCT performance.
Preparation of Leukofiltered Platelet Concentrates. Using a sterile
docking device SCD312, a buffy coat leukodepletion set, comprised
of an Autostop buffy coat filter and a 1.3-litre PL 2410 plastic con-
tainer, was connected to each of the 5 buffy coat pools. Low-speed
centrifugation (655 g, 5 min) was applied to the bag assembly to sepa-
rate the platelet-rich plasma diluted with either T-Sol or PAS III from
the red cells. After centrifugation, the platelet-rich plasma diluted
with T-Sol or PAS III was expressed into the PL 2410 bag through the
Autostop filter.
Preparation of Untreated Platelet Concentrates (1st and 2nd
Arms). The resultant leukoreduced platelet concentrate suspended in
T-Sol (1st arm) and that suspended in PAS III (2nd arm) were not
treated with PCT and were used as controls. They were stored on a
flat-bed shaker (50–60 cycles/min) for up to 7 days at 20–24°C.
Day 0 was designated as the day of collection.
Preparation of PCT Platelet Concentrates (3rd and 4th Arms).
The PCT proceeded immediately after platelet processing. The pro-
cess is described in the flow chart (fig. 1).
Fig. 1. Preparation of PCT BC-PC. FB = Filtration bag; IB = illumination bag; SRD = S-59 removal device; SB = storage bag.
Step A: Transfer of the Platelet Concentrate into the Illumination
Container. Using a sterile docking device SCD312, the platelet con-
tainer, the S-59 container and the illumination container were sterile-
connected in series. The leukoreduced platelet concentrate in plas-
ma/PAS III was passed through the S-59 solution into the PL 2410
illumination container. The air was expressed out of the illumination
container. The illumination container containing the platelet concen-
trate and S-59 was then separated from the S-59 container and the
platelet container by heat seal.
Step B: Illumination. Platelet mixture with added S-59 in the PL
2410 illumination container was placed in the UVA illumination
device. The platelet mixture was exposed to a 3 J/cm2 treatment with
UVA with agitation (60 cycles/min).
Step C: Transfer into the SRD. After UVA illumination, the illumi-
nation container was sterile-connected to an SRD. The platelet mix-
ture was transferred into the SRD. The air was expressed out of the
SRD container. After separating the SRD from the illumination bag
by heat seal, the treated platelets were stored with agitation at 20–
24°C for 9 h (3rd arm), or for 16 h (4th arm) in the SRD.
Step D: Platelet Storage. After the incubation period in an SRD, the
platelet mixture was transferred into a 1.3-litre PL 2410 plastic stor-
age container for continued storage for up to 7 days from collection
with agitation on a flat-bed shaker (50–60 cycles/min) at 20–24°C
(day 0 is day of collection).
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In vitro Platelet Assays
Platelet aliquots were drawn under sterile conditions on storage
day 1 (before addition of S-59 for arms 3 and 4), 2, 3, 5 and 7.
Haematological parameters were measured electronically (Cell
Dyn 3500, Abbott Laboratories, Chicago, Ill., USA) and leukocyte
contamination was measured microscopically in a Nageotte cham-
ber. Blood gases and bicarbonate were analysed with a 238 pH Blood
Gas System (Ciba Corning, UK).
Glucose concentration and lactate concentration were measured
in a Dimension Chemistry Analyzer (Dupont, Wilmington, Del.,
USA). ATP was measured with a chemiluminescence method in a
Lumicount counter (Packard Corp., Groningen, NL).
For estimation of platelet activation, GMP140 expression (p-
selectin) by flow cytometry was measured by two-color labelling
using a FACScan (Becton & Dickinson, San Jose, Calif., USA). FITC
labelling of platelets was performed with anti-CD42. GMP expres-
sion was determined using anti-CD62 (PE). Both reagents are manu-
factured by Becton & Dickinson. The assay method was as follows:
platelets were fixed in 1% paraformaldehyde and directly labelled
with anti-CD42 (FITC) and anti-CD62 (PE); the scatter gates were
set on the platelet population fraction; laser excitation was at
488 nm.
Hypotonic shock response was measured as described by Holm et
al. [5]. Measurements were performed on a spectrophotometer (LKB,
Ultrospect II, Cambridge, UK).
The samples for electron microscopy (EM) were prepared accord-
ing to the method described by Klinger and Kluter [6]. For test plate-
let concentrates, samples were taken on day 1 after UVA illumina-
tion and on days 2 and 5 of storage. For control platelet concentrates,
samples were taken in parallel with the test platelets on days 1, 2 and
5. Briefly, all platelet samples were embedded in Araldite resin, then
polymerized in fresh resin at 60–70°C for up to 48 h. From the sub-
sequent resin blocks produced, semi- and ultra-thin sections were cut
and collected on nickel grids. These were stained using saturated
alcoholic uranyl acetate and lead citrate, examined and images
recorded using transmission EM. A minimum of 4 images from each
sample were analyzed for platelet morphology using a final magnifi-
cation of !6,500. Platelets with abnormal morphologic ultrastruc-
ture characterized by extreme swelling and loss of cytoplasmic organ-
elles were enumerated as ‘lysed platelets’. Samples were analysed
blind-coded.
Lysed platelets can be distinguished from normal platelets, and
are characterised by extreme swelling and pallor of the cytoplasmic
contents due to the disintegration and subsequent loss of cytoplasmic
proteins and organelles such as mitochondria, the open canalicular
system as well as the microtubules which maintain their normal dis-
coid shape and their pseudopods.
Statistical Analysis
In vitro data were expressed as the arithmetic mean B SD. All
data from day 2 to day 7 were analysed using analysis of variance
(ANOVA) to determine significant differences between the four
groups of platelet concentrate treatments. The difference was consid-
ered statistically different with p ! 0.05. The analysis was performed
using StatisticaV Release 5.1 for Windows (copyright Statsoft, Inc.,
1984–1996).
Table 1. Platelet product characteristics (n = 3): comparison be-
tween T-Sol and PAS III1
Study arm Platelet
additive
solution
Unit
volume
ml
Platelet
dose
!1011
Plasma
content
%
T-Sol 357B5 4.1B0.3 32B0.6
2 PAS III 325B4 4.3B0.2 34B1.0
3 PAS III 327B22 4.1B0.1 34B0.6
4 PAS III 325B32 4.2B0.4 34B0.6
PCT range
requirement 315U4103 2.5U5.0 30U45
1 Measured on day 1.
2 Volume of platelet concentrates before addition of 17.5 ml of
S-59.
3 Volume range during UVA illumination.
Results
Platelet Product Characteristics
The unit volume, platelet yield, and plasma content of
platelet concentrates prepared from pooled buffy coats
using 300 ml T-Sol were determined (table 1). The plate-
let concentrates prepared using the same procedures but
with 280 ml of PAS III had characteristics similar to
platelet concentrates prepared in T-Sol. All platelet prod-
ucts in PAS III met the photochemical treatment target
range requirements in unit volume, platelet yield and per-
cent plasma for PCT (table 1).
In vitro Platelet Characteristics
Following PCT, platelets were compared to untreated
control platelets during 7 days of storage. The pH was sta-
ble until day 3 and fell in all groups upon further storage
(table 2). There were statistically significant differences
among study groups (p ! 0.05). However, the pH was well
maintained. At day 7, the pH in all groups was greater
than 6.8.
The O2 consumption increased from day 1 to day 3 (ta-
ble 3) and then slowly decreased in all products. A differ-
ence was observed between the PCT products and con-
trols (p ! 0.05). The level of pCO2 dropped consistently
during storage in the PCT products and fell to 25–26 mm
Hg on day 7 (table 4). In both control groups the level of
pCO2 stabilized after day 2. The concentration of HCO–3
decreased in all groups during storage but more profound-
ly in the PCT groups at day 7 (p ! 0.05) (table 5). On day 7
all groups still had greater than 4 mM HCO–3 remaining to
provide buffering of the platelet concentrates.
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Table 2. Mean measurements of pH at 37°C in the 4 groups (n = 3,
X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
7.00B0.01 7.05B0.011 7.06B0.011 7.06B0.001
2 7.02B0.01 7.05B0.001 7.01B0.001, 2 7.01B0.011, 2
3 7.02B0.01 7.03B0.011 7.00B0.001, 2 7.00B0.011, 2
5 6.96B0.01 6.98B0.01 6.93B0.011, 2 6.95B0.012
7 6.88B0.01 6.90B0.02 6.83B0.021, 2 6.85B0.022
1 p ! 0.05 compared to T-Sol control.
2 p ! 0.05 compared to PAS III control.
Table 3. Mean measurements of pO2 (mm Hg) at 37°C in the
4 groups (n = X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
86.7B5.5 87.3B5.7 107.0B11.31, 2 108.0B1.71, 2
2 58.0B13.0 58.0B13.0 72.3B1.5 79.0B8.0
3 50.7B6.1 48.7B5.7 65.0B4.61, 2 68.7B8.01, 2
5 57.3B7.2 56.0B7.5 74.7B3.11, 2 78.7B9.31, 2
7 58.7B5.9 60.3B9.1 82.7B4.7 93.7B6.7
1 p ! 0.05 compared to T-Sol control.
2 p ! 0.05 compared to PAS III control.
Table 4. Mean measurements of pCO2 (mm Hg) at 37°C in the
4 groups (n = 3, X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
33.7B0.6 32.0B1.0 31.7B1.5 31.7B0.6
2 31.7B1.2 30.7B0.6 30.3B0.6 31.3B0.6
3 31.7B1.2 31.0B1.0 28.7B0.61, 2 28.7B0.61, 2
5 32.0B1.0 30.0B1.0 27.3B0.61, 2 26.0B1.71, 2
7 33.7B1.2 30.0B1.0 25.7B0.61, 2 24.7B1.51, 2
1 p ! 0.05 compared to T-Sol control.
2 p ! 0.05 compared to PAS III control.
Table 5. Mean measurements of bicarbonate (mM ) at 37°C in the
4 groups (n = 3, X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
8.5B0.2 8.9B0.2 8.9B0.3 8.9B0.3
2 8.1B0.2 8.5B0.2 7.7B0.22 7.8B0.12
3 8.1B0.2 8.2B0.1 7.0B0.11, 2 7.2B0.21, 2
5 7.3B0.2 7.0B0.2 5.6B0.11, 2 5.7B0.41, 2
7 6.2B0.2 5.8B0.4 4.3B0.21, 2 4.3B0.51, 2
1 p ! 0.05 compared to T-Sol control.
2 p ! 0.05 compared to PAS III control.
Table 6. Mean measurements of volume ml in the 4 groups (n = 3,
X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
357B5 325B41 327B21 325B31
2 349B5 316B31 313B21 312B51
3 344B5 311B21 307B21 306B41
5 342B5 310B21 306B21 305B51
7 337B5 305B31 301B21 300B51
1 p ! 0.05 compared to T-Sol control.
Table 7. Mean measurements of platelet counts !109/l in the
4 groups (n = 3, X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
1,159B63 1,326B76 1,267B24 1,291B119
2 1,163B78 1,283B61 1,212B42 1,208B85
3 1,144B31 1,264B45 1,182B28 1,182B100
5 1,157B39 1,267B62 1,171B261, 2 1,154B811, 2
7 1,149B64 1,257B65 1,155B261 1,143B971, 2
1 p ! 0.05 compared to T-Sol control.
2 p ! 0.05 compared to PAS III control.
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Table 8. Mean measurements of plasma glucose in mmol/l in the
4 groups (n = 3, X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
7.1B0.2 7.7B0.051 7.6B0.21 7.5B0.21
2 6.7B0.05 7.2B0.051 6.7B0.12 6.9B0.21, 2
5 5.0B1.0 4.8B1.0 3.9B0.2 4.1B0.2
7 3.0B0.1 2.2B0.21 1.7B0.11, 2 2.0B0.11
1 p ! 0.05 compared to T-Sol control.
2 p ! 0.05 compared to PAS III control.
Table 9. Mean measurements of plasma lactate in mmol/l in the
4 groups (n = 3, X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
4.0B0.1 4.1B0.2 4.0B0.2 4.2B0.7
2 4.6B0.3 5.0B0.2 4.6B0.2 4.6B0.4
5 8.3B0.5 9.9B1.7 10.4B0.7 9.9B0.6
7 11.1B0.1 13.5B0.31 13.1B0.41 13.0B0.81
1 p ! 0.05 compared to T-Sol control.
Table 10. Mean measurement of total ATP Ìmol/1011 platelets in
the 4 groups (n = 6, X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
2.9B0.2 n.d. n.d. n.d.
2 2.7B0.4 n.d. n.d. 2.7B0.5
5 3.5B0.3 n.d. n.d. 3.5B0.3
7 3.1B1.1 n.d. n.d. 3.1B1.1
n.d. = Not done. There were no statistically significant differences
between groups.
An overall reduction in platelet content of approxi-
mately 15% (3rd arm) and 19% (4th arm) after 7 days was
seen in the PCT products in comparison with a reduction
of 5% (1st arm) and 12% (2nd arm) in the control prod-
ucts (p ! 0.05). This reduction was primarily due to the
volume of samples withdrawn for various function analy-
ses (table 6). A larger volume loss was observed during
PCT processing which involved transfers of platelets from
the illumination container to the SRD container and then
to the storage container. No difference was seen in platelet
counts per liter between SRD exposures of 9 and 16 h (ta-
ble 7).
The residual leukocytes after filtration ranged from
!0.1 ! 106/l to 0.3 ! 106/l in all four study groups. No
statistically significant differences were detected among
study groups. These products were considered leukore-
duced.
Mean platelet volume increased during storage in both
the PCT and control groups. However, there were no
statistically significant differences between the study
groups.
Biochemical parameters showed a fall in glucose in all
groups during storage but on day 7 a sufficient amount of
glucose was available for metabolism (table 8). No differ-
ence was seen between the groups on day 5. Lactate levels
increased as expected in all four groups during storage (ta-
ble 9). There were statistically significant differences be-
tween the T-Sol control group and the groups in PAS III at
day 7 (p ! 0.05). Analysis of total ATP showed that even
at day 7 sufficient ATP was available (table 10). There
were no statistically significant differences between the T-
Sol control group and the PCT-SRD 16-hour treated
group.
Activation marker GMP-140 showed an increase in
the proportion of activated platelets in both the control
and the PCT group during storage (table 11) with a higher
percentage of activated platelets in the PCT group (p !
0.05).
Hypotonic shock response was stable from day 1 to
day 7 during storage without any difference between the
groups (table 12). Both test and control products demon-
strated preservation of the swirling phenomenon on all
days through day 7.
Electron Microscopic Evaluation of Platelets
For the PCT study arms, day 1 analysis was performed
on platelet samples withdrawn following UVA illumina-
tion before SRD exposure. On day 2, platelet samples
were withdrawn following PCT including SRD exposure.
Platelet lysis increased during storage in all groups and
11
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Table 11. Mean measurements of GMP 140 (%) in the 4 groups
(n = 6, X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
46B4 n.d. n.d. n.d.
2 58B2 n.d. n.d. 67B21
5 73B2 n.d. n.d. 83B21
7 80B2 n.d. n.d. 86B21
n.d. = Not done.
1 p ! 0.05 compared to T-Sol control.
Table 12. Mean percentage of HSR in the 4 groups (n = 3, X B SD)
Day T-Sol PAS III PCT-SRD
9 h 16 h
60.0B9.6 54.3B13.2 52.3B10.0 59.0B9.6
2 58.3B7.5 60.0B6.8 51.7B2.1 58.0B2.0
5 55.3B7.5 51.7B6.0 59.0B2.0 57.0B2.6
7 53.0B6.6 48.3B0.6 51.7B4.0 49.3B4.9
There were no statistically significant differences between all
groups.
greater levels of platelet lysis were observed in the PCT
groups (table 13) compared to controls (p ! 0.05). The
observed platelet lysis apparently did not result in a
change in platelet counts. No platelet count (!109/l) dif-
ference was seen between SRD exposures of 9 and 16 h
(table 7).
Discussion
The use of whole-blood buffy coats for platelet concen-
trate preparation using a balanced mixture of plasma and
platelet-additive solution is an established method [7, 8].
To prepare a platelet concentrate for an adult patient, gen-
erally 4–8 buffy coats are pooled to provide a therapeutic
dose, theoretically increasing the risk of viral and bacte-
rial contamination of the pooled platelet concentrate.
Bacterial contamination in platelet concentrates has been
reported in 0.1–0.5% [9–11] of concentrates. The poten-
tially serious effects of platelet concentrates contaminated
with pathogenic micro-organisms are well known.
A PCT process to inactivate both viruses and bacteria
in platelet concentrates has been developed using single-
donor apheresis platelet concentrates [2, 3, 12].
For photochemical treatment, single-donor platelets
were suspended in approximately 300 ml of 35% plasma
and 65% of a new platelet additive solution (PAS III) and
exposed to 150 ÌM of the psoralen S-59 and a 3 J/cm2
Table 13. Platelet lysis (%) as assessed by
electron microscopy (n = 3) Study
arm
Description Lysis, %1
day 1 day 2 day 5
Platelets in plasma/T-Sol 1.02 1.6B1.4 3.7B0.2
2 Platelets in plasma/PAS III 02 2.9B1.6 5.5B0.6
3 Platelets in plasma/PAS III, PCT, 9 h SRD 0.2B0.2 5.5B3.73 14.3B4.73, 4
4 Platelets in plasma/PAS III, PCT, 16 h SRD 0.2B0.2 5.5B3.23 17.0B2.93, 4
1 The proportions of lysed platelets were determined by enumeration of intact and lysed
platelets in electron micrographs. Blinded observers counted at least 193 platelets in each
sample. All values represent the mean B SD expressed as a percent of the total platelets
counted in each group.
2 All groups with n = 3 at each sampling day with the exception of the 2 untreated controls
on day 1, n = 1.
3 p ! 0.05 compared to T-Sol control.
4 p ! 0.05 compared to PAS III control.
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treatment with long wave length ultraviolet light (UVA
320–400 nm). Under these conditions, high levels of vi-
ruses, bacteria and leukocytes were inactivated [2–4].
This study assessed the application of PCT to platelets
prepared from pooled buffy coats.
Preliminary studies suggested the optimal PCT condi-
tions were plasma concentration within the critical limits
of 30–45% of the total volume. These conditions also are
compatible with the pooled buffy coat method of platelet
preparation utilizing T-Sol, a platelet storage medium
similar to PAS III. Prior to a clinical transfusion study
with PCT platelet concentrates, we conducted an in vitro
study to evaluate the characteristics of pooled buffy coat
concentrates in plasma and PAS III subjected to PCT and
7 days of storage. These studies were also used to develop
standardized procedures for production and quality con-
trol of PCT platelet concentrates.
The in vitro platelet function studies showed no evi-
dence of metabolic deterioration of platelets after PCT and
subsequent storage for up to 7 days. The pH (37°C) of PCT
platelets was maintained above 6.8 throughout the 7 days
of storage. PCT did not stimulate glycolysis. Similar levels
of glucose remained on day 7 for the control group with
PAS III and the PCT groups. Consequently, lactate levels
of PCT platelets on day 7 were comparable to control plate-
lets in PAS III. At day 7, a sufficient amount of glucose was
still available for metabolism using the current preparation
methods (residual plasma of 34 B 1%). No difference was
detected in total ATP at day 7 among the various study
groups, confirming that platelet metabolism was con-
served. Although other studies have shown an effect of
UVA light on cellular mitochondrial membrane potential
[13], PCT did not affect total platelet ATP content up to 7
days of storage indicating that platelet mitochondrial func-
tion was conserved. Maintenance of the ATP level corre-
lates with platelet viability [14]. Furthermore, the hypo-
tonic shock response analysis was consistent with preserva-
tion of platelet energy metabolism.
Due to repeated sampling for platelet analysis and sev-
eral transfers between platelet containers during PCT pro-
cessing, the platelet content in both PCT groups was lower
compared to the control groups. The difference in platelet
content may have accounted for some of the differences in
pO2, pCO2, and HCO–3 between the control groups and
the PCT groups. The activation marker GMP-140 (p-
selectin) showed a greater increase during storage in the
PCT groups. However, it is not clear from the literature
whether in vitro p-selectin expression correlates with in
vivo viability. Shortened survival of activated platelets
after transfusion has been reported in studies on platelet
apheresis [15–17]. On the other hand, it was also reported
that expression of the p-selectin epitope recognized by the
CD62 antibody does not correlate with in vivo platelet
recovery [18]. The proportion of lysed platelets, as as-
sessed by electron microscopy, on day 5 in both photo-
chemically treated groups was higher than that of the con-
trol arms. It is presently unknown whether there was ran-
dom loss of platelets or whether older platelets were more
susceptible to lysis. The higher p-selectin levels, subtle
changes in respiratory activity, and a higher proportion of
platelets with altered morphology may represent an effect
of PCT on small numbers of older platelets [19].
Prior studies with 5-day-old single-donor platelets
have demonstrated a small decrease in post-transfusion
recovery and life span, but within an acceptable range for
therapeutic support of thrombocytopenic patients [20].
Recently, studies in patients have demonstrated that PCT
platelets gave an adequate platelet count increment, cor-
rected prolonged bleeding times, and the interval to the
next platelet transfuison was comparable to standard
platelets [21].
The current BC-PC preparation process with a limited
content of plasma (34 B 1%) allows good maintenance of
in vitro platelet function. A method was developed to con-
trol the proportion of plasma in BC-PC preparations for
PCT by using the volume of the residual pooled buffy
coat, the haematocrit of the residual pooled buffy coat
and the volume of the buffy coat PC. The production pro-
cess, which requires extra hands-on time, can be orga-
nized in such a way in the blood bank that a full time
availability to the patients in hospital can be maintained.
In conclusion, the results from the in vitro studies indi-
cate that PCT is compatible with platelet concentrates
prepared from pooled buffy coats for up to 7 days of stor-
age. These PCT pooled buffy coat platelets are currently
in a clinical trial to evaluate the post-transfusion platelet
count increment and the haemostatic efficacy in throm-
bocytopenic patients.
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